Clinical Trials Logo

Clinical Trial Details — Status: Terminated

Administrative data

NCT number NCT01128712
Other study ID # NEREG-001
Secondary ID
Status Terminated
Phase Phase 4
First received May 20, 2010
Last updated September 12, 2017
Start date April 2010
Est. completion date July 2014

Study information

Verified date September 2017
Source Northeast Regional Epilepsy Group
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

To prospectively demonstrate the superior anxiolytic effect of high dose pregabalin (PGB) therapy (450 mg/day) compared to low dose PGB therapy (150 mg/day) in subjects with medically refractory partial epilepsy not fully controlled despite treatment with 1-2 concomitant antiepileptic drugs (AEDs).


Description:

Background

Interictal anxiety symptoms are reported in two-thirds of patients with epilepsy and represent an underrecognized and undertreated aspect of the disorder. Interictal anxiety is postulated to stem from both fear of seizure recurrence ("seizure phobia") and dispersed locus of control.In addition, anxiety and the most common forms of partial onset epilepsy are viewed to arise from dysfunction in a common neurobiological substrate-the amygdala and other structures within the limbic system.

Background on Pregabalin

Pregabalin (CI-1008,Lyrica) is a chemical analogue of the mammalian neurotransmitter gamma-aminobutyric acid (GABA),although it does not bind to or activates GABA receptors or inhibit GABA uptake. Pregabalin is an alpha-2-delta ligand that has analgesic, anxiolytic, and antiepileptic activity.

Rationale

Antiepileptic drugs (AEDs) are commonly used for mood disorders including anxiety.Pregabalin (PGB) the most recently FDA-approved AED for add-on therapy for refractory partial seizures also has demonstrated efficacy in Generalized Anxiety Disorder. PGB binds to the alpha-2-delta subunit protein of voltage-gated calcium channels, and in animal models, has anxiolytic and anti-epileptic effects via pre-synaptic inhibition of the release of several excitatory neurotransmitters.


Recruitment information / eligibility

Status Terminated
Enrollment 4
Est. completion date July 2014
Est. primary completion date July 2014
Accepts healthy volunteers No
Gender All
Age group 18 Years to 75 Years
Eligibility Inclusion Criteria

- An IRB-approved consent form signed and dated by the subject

- A diagnosis of partial epilepsy which is drug resistant according to the International League Against Epilepsy criteria (Failure of adequate trials of two tolerated and appropriately chosen and used AED schedules (whether as monotherapies or in combination) to achieve sustained seizure freedom). Furthermore to meet the ILAE definition of drug resistance, subjects will have had breakthrough seizures occurring at a frequency of less than 3 times the longest pretreatment interseizure interval or every 12 months, which ever is longer.

- Subjects that score =18 on Beck Anxiety Inventory will be included in the study

- Subjects from 18 to 75 years, both inclusive.

- Females without childbearing potential or childbearing potential using medically accepted forms of birth control (pre-menarcheal, post-menopausal, bilateral oophorectomy or tubal ligation, complete hysterectomy, or medically accepted form of contraception).

- Subject judged by the Investigator to be reliable and capable of adhering to the protocol, visit schedules, and able to understand and complete study instruments.

- CT or MRI scan performed within 2 years of screening and without evidence of a progressive lesion or neurological condition.

- Electroencephalogram consistent with partial epilepsy and does not demonstrate generalized spike wave.

- Currently treated with a stable dose of 1-2 AEDs for a minimum of 4 weeks (3 months for phenobarbital and primidone). Benzodiazepines used as a rescue therapy for seizures and used no more than once a week will be permitted.

Exclusion Criteria

- History of psychogenic non-epileptic seizures.

- The subject is pregnant or lactating.

- Women with reproductive potential who refuse to use medically accepted forms of birth control.

- Presence of any clinically significant laboratory abnormality which in the judgement of the investigator should exclude the subject from the study.

- Presence of any progressive, demyelinating, or degenerative neurological condition.

- Subject is currently taking gabapentin.

- History of an allergic reaction to gabapentin or PGB.

- History of worsened seizures or serious adverse reactions to gabapentin.

- History of suicide attempt.

- No active suicidal plan/intent or active suicidal thoughts in the last 6 months.

- Current use or use within the previous three months prior to screening of antidepressant, anxiolytic, or antipsychotic agents. Subjects using benzodiazepines for anxiety will not be permitted.

- Diagnosis of Bipolar Disorder, Schizophrenia, psychotic disorder (excluding post-ictal psychosis), Major Depression requiring hospitalization in the past 2 years, or other psychological or behavioral condition which in the judgement of the investigator should exclude the subject from the study.

- A history of alcoholism, drug abuse, or drug addiction within the last 2 years.

- Any contraindication to use of PGB.

- Any clinical condition (e.g. severe renal impairment, chronic hepatic disease, serious infection, and or bone marrow depression) which will impair participation in the trial.

- History of multiple drug allergies or severe drug allergy.

- Subjects with vagal nerve stimulators (VNS).

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Pregabalin
150 mg /day
Pregabalin
450 mg/day

Locations

Country Name City State
United States Northeast Regional Epilepsy Group Hackensack New Jersey

Sponsors (2)

Lead Sponsor Collaborator
Northeast Regional Epilepsy Group Pfizer

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Change in Beck Anxiety Score The primary outcome variable will be the change in the Beck Anxiety Inventory (BAI) score as measured at the baseline and final visits. week 0 - week 6
Secondary Change in BDI , NHS3 , STAI , NDDI-E and seizure frequency The secondary outcome variables will be the change in the Beck Depression Inventory, change in National Hospital Seizure Severity Scale (NHS3) score, change in seizure frequency, change in Stait-Trait Anxiety Scale (STAI),and change in the National Disorders Depression Inventory for Epilepsy Screening Tool (NDDI-E) as measured at the baseline and final visits. week 0 - week 6
See also
  Status Clinical Trial Phase
Completed NCT00143143 - Pregabalin Open-Label Extension Trial in Patients With Partial Seizures Phase 3
Completed NCT01002820 - A Treatment Use Protocol for Subjects Continuing on From the Open-label Extension 0601 Phase 2
Completed NCT00001489 - Effect of Vigabatrin on Brain Blood Flow and Glucose Metabolism N/A
Completed NCT00425282 - A Study of the Efficacy and Safety of RWJ-333369 as add-on Therapy in the Treatment of Partial Onset Seizures. Phase 3
Completed NCT00433667 - A Study of the Efficacy and Safety of RWJ-333369 as add-on Therapy in the Treatment of Partial Onset Seizures. Phase 3
Completed NCT03156439 - Bioavailability, Safety, and Tolerability of BIS-001 ER Phase 1
Completed NCT04573569 - Neural Correlates of Cognition and Mood
Completed NCT00744731 - An Open-Label Extension Study of the Safety and Tolerability of Carisbamate as Add-On Therapy in Patients With Partial Onset Seizures Phase 3
Completed NCT00740623 - A Study of the Effectiveness, Safety, and Tolerability of Carisbamate as Add-On Therapy in Patients With Partial Onset Seizures. Phase 3
Completed NCT00319501 - Efficacy and Safety of Vanquix for the Management of Selected, Refractory, Patients With Epilepsy Who Require Intermittent Caregiver Medical Intervention to Control Episodes of Acute Repetitive Seizures. Phase 3
Completed NCT00991757 - An Open-Label Extension Study to Evaluate the Safety and Tolerability of RWJ 333369 as Adjunctive Therapy in Patients 16 Years and Older With Partial Onset Seizures. Phase 3
Completed NCT00056576 - Dose Response Study of Zonegran in Patients With Newly Diagnosed Epilepsy Phase 3